Sidley represented AstraZeneca China in a strategic collaboration with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences). AstraZeneca China will be granted exclusive promotion rights to anti-PD-1 cancer drug Toripalimab Injection (trade name: TUOYI®) for urothelial carcinoma across China, and all other indications outside core urban areas when they are approved. Toripalimab is an anti-PD-1 monoclonal antibody injection for the treatment of certain cancers.
AstraZeneca has a deep-rooted history and a leading position in the treatment of lung, breast, ovary, and prostate cancers in China. It also launched four scientific platforms —Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, and Antibody Drug Conjugates. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody drugs in China. The strategic alliance will help to speed up the rolling-out of innovative drugs to the wider population in China.
The Sidley team was led by partner Lei Li and senior counsel Chen Yang, with the support of counsel Jing Lu.
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for startups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, refinancings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.
